Structure-Based Drug Design to Perturb Function of a tRNA-Modifying Enzyme by Active Site and Protein-Protein Interface Inhibition

  • Gerhard Klebe
Conference paper
Part of the NATO Science for Peace and Security Series A: Chemistry and Biology book series (NAPSA)


Drug research increasingly focuses on the interference with protein-protein interface formation as attractive opportunity for therapeutic intervention. The tRNA-modifying enzyme Tgt, a putative drug target to fight Shigellosis, is only functionally active as a homodimer. To better understand the driving forces responsible for assembly and stability of the formed homodimer interface we embarked onto a computational and mutational analysis of the interface-forming residues. We also launched spiking ligands into the interface region to perturb contact formation. We controlled by non-degrading mass spectrometry the actual ratio of monomer-dimer equilibrium in solution and used crystal structure analysis to elucidate the geometrical changes resulting from the induced perturbance. A patch of four aromatic amino acids, embedded into a ring of hydrophobic residues and further stabilized by a network of H-bonds is essential for the dimer contact. Apart from the aromatic hot spot, the interface shows an extended loop-helix motif, which exhibits remarkable flexibility. In the destabilized mutant variants and the complexes with the spiking ligands, the loop-helix motif adopts deviating conformations in the interface region. This motivated us to follow a strategy to raise small molecule binders against this motif to mould the loop geometry in a conformation incompatible with the interface formation.


Aromatic Amino Acid Dime Interface Monomeric State Binding Stoichiometry tRNA Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Klebe G (2013) Drug design, Chapter 21, Springer Reference, Heidelberg, New York, Dordrecht, London. doi: 10.1007/978-3-642-17907-5
  2. 2.
    Romier C, Ficner R, Reuter K, Suck D (1996) Purification, crystallization, and preliminary x-ray diffraction studies of tRNA-guanine transglycosylase from Zymomonas mobilis. Proteins Struct Funct Genet 24:516–519CrossRefPubMedGoogle Scholar
  3. 3.
    Grädler U, Gerber HD, Goodenough-Lashua DM, Garcia GA, Ficner R, Reuter K, Stubbs MT, Klebe G (2001) A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase. J Mol Biol 306:455–467CrossRefPubMedGoogle Scholar
  4. 4.
    Stengl B, Reuter K, Klebe G (2005) Mechanism and substrate specificity of tRNA – guanine transglycosylases (TGTs): tRNA modifying enzymes from thee three different kingdoms of life seem to share a common mechanism. ChemBioChem 6:1–15CrossRefGoogle Scholar
  5. 5.
    Brenk R, Naerum L, Grädler U, Gerber HD, Garcia GA, Reuter K, Stubbs MT, Klebe G (2003) Virtual screening for submicromolar leads of TGT based on a new unexpected binding mode detected by crystal structure analysis. J Med Chem 46:1133–1143CrossRefPubMedGoogle Scholar
  6. 6.
    Meyer EA, Donati N, Guillot M, Schweizer B, Diederich F, Stengl B, Brenk R, Reuter K, Klebe G (2006) Synthesis, biological evaluation, and crystallographic studies of extended guanine-based (lin-benzoguanine) inhibitors for tRNA-guanine transglycosylase (TGT). Helv Chim Acta 89:573–597CrossRefGoogle Scholar
  7. 7.
    Hörtner S, Ritschel T, Stengl B, Kramer C, Klebe G, Diederich F (2007) Potent inhibitors of tRNA-guanine transglycosylase, an enzyme linked to the pathogenicity of the Shigella bacterium: charge-assisted hydrogen bonding. Angew Chem Int Ed 46:8266–8269CrossRefGoogle Scholar
  8. 8.
    Ritschel T, Kohler PC, Neudert G, Heine A, Diederich F, Klebe G (2009) How to replace the residual solvation shell of polar active site residues to achieve nanomolar inhibition of tRNA-guanine transglycosylase. ChemMedChem 4:2012–2023CrossRefPubMedGoogle Scholar
  9. 9.
    Kohler PC, Ritschel T, Schweizer WB, Klebe G, Diederich F (2009) High-affinity inhibitors of tRNA-guanine transglycosylase replacing the function of a structural water cluster. Chem Eur J 15:10809–10817CrossRefPubMedGoogle Scholar
  10. 10.
    BarandunL IF, Kohler PC, Ritschel T, Heine A, Orlando P, Klebe G, Diederich F (2013) High-affinity inhibitors of Zymomonas mobilis tRNA–guanine transglycosylase through convergent optimization. Acta Crystallogr D69:1798–1807Google Scholar
  11. 11.
    Stengl B, Meyer EA, Heine A, Brenk R, Diederich F, Klebe G (2007) Crystal structures of tRNA-guanine transglycosylase (TGT) in complex with novel and potent inhibitors unravel pronounced induced-fit adaptations and suggest dimer formation upon substrate binding. J Mol Biol 370:492–511CrossRefPubMedGoogle Scholar
  12. 12.
    Xie W, Liu X, Huang RH (2003) Chemical trapping and crystal structure of a catalytic tRNA guanine transglycosylase covalent intermediate. Nat Struct Biol 10:781–788CrossRefPubMedGoogle Scholar
  13. 13.
    Ritschel T, Atmanene C, Reuter K, Van Dorsselaer A, Sanglier-Cianferani S, Klebe G (2009) An integrative approach combining noncovalent mass spectrometry, enzyme kinetics and X-ray crystallography to decipher Tgt protein-protein and protein-RNA interaction. J Mol Biol 393:833–847CrossRefPubMedGoogle Scholar
  14. 14.
    Gohlke H, Kiel C, Case DA (2003) Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol 330:891–913CrossRefPubMedGoogle Scholar
  15. 15.
    Jakobi S, Nguyen TXP, Debaene F, Metz A, Sanglier-Cianferani S, Reuter K, Klebe G (2014) Hot-spot analysis to dissect the functional protein–protein interface of a tRNA-modifying enzyme. Proteins Struct Funct Bioinform 82:2713–32PubMedGoogle Scholar
  16. 16.
    Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1–9CrossRefPubMedGoogle Scholar
  17. 17.
    Immekus F, Barandun LJ, Betz M, Debaene F, Petiot S, Sanglier-Cianferani S, Reuter K, Diederich F, Klebe G (2013) Launching spiking ligands into a protein–protein interface: a promising strategy to destabilize and break interface formation in a tRNA modifying enzyme. ACS Chem Biol 8:1163–1178CrossRefPubMedGoogle Scholar
  18. 18.
    Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein–protein interactions: progressing towards the dream. Nat Rev Drug Discov 3:301–317CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Department of Pharmaceutical ChemistryUniversity of MarburgMarburgGermany

Personalised recommendations